

4DMEDICAL COMPLETES FIRST COMMERCIAL SCAN IN AUSTRALIA

- First commercial use of 4DMedical's XV Lung Ventilation Analysis Software (XV LVAS™) completed successfully in Victoria, Australia
 - Installations of XV LVAS anticipated across Australia from early 2021 as national infrastructure is established by 4DMedical
 - Achieved ahead of schedule, the first commercial scan marks a key milestone for the commercialisation of 4DMedical's XV Technology™
-

18 December 2020: 4DMedical Limited (ASX:4DX, "4DMedical" or the "Company"), a medical technology company focused on commercialising its patented respiratory imaging platform, is pleased to announce that it has delivered the first XV Lung Ventilation Analysis Software (XV LVAS) scan to an Australian patient.

The scan was successfully completed in Victoria and marks the first commercial use of XV LVAS as the Company begins to roll out its infrastructure nationally. Installation of XV LVAS is anticipated in hospitals and imaging centres in Victoria as well as other states from early 2021.

As part of the national rollout, hospitals and imaging centres will be able to offer 4DMedical's lung report in both inpatient and outpatient settings – maximising the number of addressable patients in Australia.

The delivery of the first XV LVAS scan comes after the Company received TGA approval for the technology, six months ahead of schedule, in September 2020.

Utilising 4DMedical's proprietary XV Technology, XV LVAS converts sequences of X-ray images into four-dimensional quantitative data by using patented mathematical models and algorithms. XV LVAS is the Company's first Software-as-a-Service (SaaS) offering and can provide immediate benefits to Australian physicians and patients, including assisting in the ability for physicians to diagnose respiratory diseases earlier and with more sensitivity while using existing hospital and clinical equipment.

Andreas Fouras, Founder & CEO of 4DMedical said:

"We're pleased to hit yet another milestone ahead of schedule and see our end-to-end SaaS clinical solution perform flawlessly in a real-world setting. COVID-19 has seen traditional spirometry assessments shut down and our technology also provides an excellent alternative for patients who need regular and more detailed lung health assessments. While this might be our first ever Australian patient report, we expect to scale up quickly and begin to make a real difference to lung health in Australia."

ENDS

Authorised by the 4DMedical Board of Directors.

Contacts:

Corporate

Charlene Stahr
Company Secretary
companysecretary@4dmedical.com

Investor

Simon Hinsley
+ 61 401 809 653
shinsley@4dmedical.com

Media

Matthew Wright
+ 61 451 896 420
matt@nwrcommunications.com.au

About 4DMedical:

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical (formerly 4Dx) was founded in 2012 and is listed on the Australian Securities Exchange (ASX: 4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnosis is a US\$31 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.